Press releases
- Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors
- Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
- Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
- Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
- Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
More ▼
Key statistics
As of last trade, Akeso Inc (9926:HKG.HS) traded at 36.65, 38.56% above the 52 week low of 26.45 set on May 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 38.90 |
---|---|
High | 39.05 |
Low | 36.55 |
Bid | 36.65 |
Offer | 36.70 |
Previous close | 38.90 |
Average volume | 5.14m |
---|---|
Shares outstanding | 865.86m |
Free float | 634.96m |
P/E (TTM) | 14.95 |
Market cap | 33.68bn HKD |
EPS (TTM) | 2.60 HKD |
Data delayed at least 15 minutes, as of Jul 08 2024.
More ▼